FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 12:58:00 2024-05-23 EDT | ||
| 7.61 EUR | -9.40% |
|
| Current month | -18.13% | ||
| 1 month | -28.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 7.61 | -9.40% |
| 24-05-22 | 8.4 | +1.08% |
| 24-05-21 | 8.31 | -7.97% |
| 24-05-20 | 9.03 | -4.85% |
| 24-05-17 | 9.49 | +5.56% |
Real-time Boerse Frankfurt Warrants
Last update May 23, 2024 at 12:58 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7Q5T |
| ISIN | DE000SW7Q5T4 |
| Date issued | 2024-03-15 |
| Strike | 908 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.6 € |
|---|---|
| Lowest since issue | 7.53 € |
| Spread | 0.37 € |
| Spread % | 4.68% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Certificat
